In 2025, the pharmacy market will be worth 47.7 billion euros, according to Iqvia. It increases by 4.8% in value between July 2024 and July 2025. This market, however, declines by 0.3% in units. This reflects a decrease in sales volumes, which is offset by continued growth in expensive medicines.
Lower than in past years
Still according to Iqvia statistics, the average turnover (CA) all taxes included (TTC) per pharmacy rose to 2.41 million euros in July 2025, showing growth of + 6.3% since July 2024. At Fiducial also, “the first data concerning the first half of 2025 show an increase in turnover, but much less strong than in previous years, says Bertrand Cadillon, accountant responsible for the pharmacy market. It would rather be of the order of +2 to +3%, due in particular to reductions in the price of medicines.” According to Gers Data, these, in the city alone, have generated more than 1 billion euros gross (manufacturer price excluding taxes) in savings for Social Security in 2025.
Already in 2024, the Pharmacy Management Council (CGP) network recorded growth in pharmacy turnover of 5%, still drained by the prices of expensive drugs but “masking a significant acceleration in price reductions for reimbursed medicines, well above the trajectory set by the Social Security financing law for 2024, with more than 500 million euros in additional savings made compared to the 850 million planned”. CGP also noted, on its panel in 2024, a contraction in sales volumes and visits to pharmacies. This would increase by 1.6% on average, week after week, according to statistics provided by Iqvia.
“As in previous years, during 2024 we will see significant disparities from one pharmacy to another, notes Louis Maertens, chartered accountant in Lille for the FCC firm, member of the CGP network. Pharmacies with a turnover of more than 2.5 million euros excluding taxes are performing at almost 6% growth, while those with a turnover of less than 1 million euros are seeing a further negative development in their activity. »
According to Rydge Conseil, mid-sized pharmacies (turnover between 1.1 million and 2.2 million euros) recorded the most dynamic growth (+5.3%), driven by a balanced positioning between proximity, services and product offering. Conversely, small structures (turnover less than 1.1 million euros) show a slight contraction in their turnover (-0.3%), often linked to resource constraints or a lesser capacity to adapt, notes Rydge Conseil.
From the point of view of the CGP network, “pharmacies in rural areas and large towns are doing the best, observe Louis Maertens. They seem less affected by the drop in attendance and volumes.” The only problem is that these pharmacies no longer attract buyers.
To get an idea of the health of pharmacies, in a context where turnover is increasingly disconnected from margins and no longer reflects the profitability of a pharmacy, experts now prefer to rely on margin value, gross operating surplus and commercial and management performance.
